CTIS2023-507203-55-00招募中1 期
Phage4Cure-001
Charite Research Organisation GmbH0 个研究点目标入组 32 人开始时间: 2023年7月21日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 发起方
- 入组人数
- 32
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 65+（—）
- 性别
- All
入选标准
- 未提供
排除标准
- 未提供
研究者
相似试验
进行中（未招募）
1 期
A two part, randomized, double-blind, placebo-controlled, parallel group SAD and MD clinical study to evaluate the safety, tolerability and preliminary efficacy of an inhaled (nebulized) phage cocktail in healthy subjects and in patients with chronic colonization of the lung with Pseudomonas aeruginosaCTIS2022-503145-22-00Charite Research Organisation GmbH32
进行中（未招募）
1 期
A trial in healthy volunteers to study safety, tolerability, CS014-levels and effects in the body, after single and repeated doses of CS014, for the first time in humans.Cardiovascular diseaseCTIS2024-510878-24-00Cereno Scientific AB48
招募中
1 期
A study in healthy subjects investigating the safety, tolerability and concentrations of FE 999301 after single and multiple dosesInflammatory Gastrointestinal DiseaseMedDRA version: 20.0Level: HLGTClassification code: 10017969Term: Gastrointestinal inflammatory conditions Class: 10017947CTIS2023-507882-24-00Ferring Pharmaceuticals A/S48
进行中（未招募）
1 期
A study investigating the safety, tolerability, absorption, excretion and effects of a new drug for the treatment of epilepsy.EpilepsyCTIS2022-502638-17-00Trevena Inc.24
进行中（未招募）
1 期
Dosimetry of a novel amino acid PET tracer, [18F]FELPGlioblastomaCTIS2022-501696-91-00niversitair Ziekenhuis Gent10